SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Appointment of David Jacques as Vice President Research
Development.

Effective February 28, 2017 Mr. Jacques joined Second Sight
Medical Products, Inc. (the Company) as
Vice President Research Development.

Mr. Jacques, age 54, has from 2012 through 2016 been a principal
of his management consulting firm where his clients included
various high tech companies including Second Sight Medical
Products, Inc.. His duties and responsibilities included
analyzing existing and leading edge technologies, aiding in
assembly of world class engineering teams, working with
management to devise innovative systems and continuous
improvement of enterprise systems, and managing multiple complex
projects. From 2012 to 2014 Mr. Jacques also was founder and
Chief Technology Officer of AcuteTeleCare, LLC, a developer of a
next generation, state of the art telemedicine platform to
facilitate rapid diagnosis and treatment for patients with acute
conditions, such as cerebral stroke. From 2006 to 2012 Mr.
Jacques also served as Vice President, Research Development at
Stereotaxis, Inc. where he was the company leader of all
engineering teams specializing in organizational evaluation, role
identification and structural effectiveness for a high-tech
leading edge medical manufacturer. He earned a Bachelor of
Science, Electrical Engineering degree from the University of
Arizona.

There is no family relationship between Mr. Jacques and the
Companys officers and directors. Other than the employment terms
described below, and the consulting services provided to the
Company as noted above, for which he received over $122,000 in
2016, Mr. Jacques and the Company have not entered into any
transaction, nor is any transaction proposed, which would require
disclosure to Item 404(a) of Regulation S-K.

Mr. Jacques will be paid an annual salary of $250,000 and will be
entitled to receive an annual cash bonus of up to 30% of base
annual salary that will be based on board established performance
standards and goals to be met by Mr. Jacques. Mr. Jacques was
also allowed a one-time payment of $15,000 to cover his
relocation and moving costs.

The board of directors has approved the grant to Mr. Jacques of
options to purchase 150,000 shares of common stock to the Second
Sight Medical Products 2011 Equity Incentive Plan, at a strike
price of $1.67 per share. These options vest over a four year
term of which 37,500 options vest on February 28, 2018, with the
remaining options vesting quarterly over three years thereafter.

Mr. Jacques employment with the Company is at will and may be
terminated with or without cause at any time. Mr. Jacques is
entitled to severance compensation in the event of termination in
accordance with the Companys severance plan. In the event Mr.
Jacquess employment terminates all unvested options will
immediately lapse, and any vested, but unexercised options will
expire 30 days from the date of the termination of employment.

ITEM 8.01 Other Events

On March 2, 2016 the Company issued a press release announcing
the appointment of David Jacques as Vice President Research
Development. A copy of the Companys press release entitled Second
Sight Appoints David Jacques as Vice President Research
Development is furnished as Exhibit99.1 to this Current Report on
Form8-K.

ITEM 9.01 Financial Statements and Exhibits

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session down -0.08 at 1.47 with 875,196 shares trading hands.